EDIT
Income statement / Annual
Last year (2023), Editas Medicine, Inc.'s total revenue was $78.12 M,
an increase of 296.32% from the previous year.
In 2023, Editas Medicine, Inc.'s net income was -$153.22 M.
See Editas Medicine, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$78.12 M
|
$19.71 M
|
$25.54 M
|
$90.73 M
|
$20.53 M
|
$31.94 M
|
$13.73 M
|
$6.05 M
|
$1.63 M
|
$0.00
|
| Cost of Revenue |
$177.65 M |
$6.34 M |
$5.05 M |
$158.00 M |
$96.90 M |
$90.65 M |
$83.16 M |
$56.98 M |
$18.85 M |
$5.07 M |
| Gross Profit |
-$99.53 M |
$13.38 M |
$20.49 M |
-$67.26 M |
-$76.37 M |
-$58.72 M |
-$69.43 M |
-$50.93 M |
-$17.22 M |
-$5.07 M |
| Gross Profit Ratio |
-1.27 |
0.68 |
0.8 |
-0.74 |
-3.72 |
-1.84 |
-5.06 |
-8.41 |
-10.57 |
0 |
| Research and Development
Expenses |
$177.65 M
|
$174.96 M
|
$142.51 M
|
$158.00 M
|
$96.90 M
|
$90.65 M
|
$83.16 M
|
$56.98 M
|
$18.85 M
|
$5.07 M
|
| General & Administrative
Expenses |
$69.65 M
|
$70.70 M
|
$76.18 M
|
$67.58 M
|
$64.56 M
|
$55.01 M
|
$50.50 M
|
$46.26 M
|
$18.10 M
|
$7.65 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$69.65 M
|
$70.70 M
|
$76.18 M
|
$67.58 M
|
$64.56 M
|
$55.01 M
|
$50.50 M
|
$46.26 M
|
$18.10 M
|
$7.65 M
|
| Other Expenses |
$0.00 |
$1.29 M |
-$1.70 M |
$16.26 M |
-$137,000.00 |
$328,000.00 |
$587,000.00 |
-$57,000.00 |
-$37.45 M |
-$928,000.00 |
| Operating Expenses |
$247.30 M |
$245.66 M |
$218.69 M |
$225.57 M |
$161.45 M |
$145.66 M |
$133.66 M |
$103.24 M |
$36.94 M |
$12.72 M |
| Cost And Expenses |
$247.30 M |
$245.66 M |
$218.69 M |
$225.57 M |
$161.45 M |
$145.66 M |
$133.66 M |
$103.24 M |
$36.94 M |
$12.72 M |
| Interest Income |
$17.57 M |
$4.23 M |
$2.34 M |
$2.61 M |
$7.31 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Interest Expense |
$0.00 |
$4.23 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$978,000.00 |
$0.00 |
$143,000.00 |
$34,000.00 |
| Depreciation &
Amortization |
$6.06 M
|
$6.34 M
|
$5.05 M
|
$3.96 M
|
$2.83 M
|
$3.25 M
|
$2.68 M
|
$1.20 M
|
$471,000.00
|
$157,000.00
|
| EBITDA |
-$163.12 M
|
-$219.61 M
|
-$188.09 M
|
-$130.88 M
|
-$138.09 M
|
-$110.47 M
|
-$116.66 M
|
-$96.07 M
|
-$72.29 M
|
-$13.49 M
|
| EBITDA Ratio |
-2.09 |
-11.46 |
-7.56 |
-1.49 |
-6.87 |
-3.55 |
-8.69 |
-16.07 |
-44.66 |
0 |
| Operating Income Ratio
|
-2.17
|
-11.46
|
-7.56
|
-1.49
|
-6.86
|
-3.56
|
-8.74
|
-16.06
|
-21.68
|
0
|
| Total Other
Income/Expenses Net |
$15.96 M
|
$5.52 M
|
$644,000.00
|
$18.86 M
|
$7.18 M
|
$3.77 M
|
-$391,000.00
|
$5,000.00
|
-$37.59 M
|
-$962,000.00
|
| Income Before Tax |
-$153.22 M |
-$220.43 M |
-$192.50 M |
-$115.98 M |
-$133.75 M |
-$109.95 M |
-$120.32 M |
-$97.18 M |
-$72.90 M |
-$13.69 M |
| Income Before Tax Ratio
|
-1.96
|
-11.18
|
-7.54
|
-1.28
|
-6.51
|
-3.44
|
-8.76
|
-16.06
|
-44.75
|
0
|
| Income Tax Expense |
$0.00 |
-$16.08 M |
-$7.40 M |
-$6.56 M |
-$10.28 M |
-$3.12 M |
-$1.12 M |
-$1.32 M |
-$37.77 M |
-$894,000.00 |
| Net Income |
-$153.22 M |
-$204.35 M |
-$185.11 M |
-$109.41 M |
-$123.47 M |
-$109.95 M |
-$120.32 M |
-$97.18 M |
-$72.90 M |
-$13.69 M |
| Net Income Ratio |
-1.96 |
-10.37 |
-7.25 |
-1.21 |
-6.01 |
-3.44 |
-8.76 |
-16.06 |
-44.75 |
0 |
| EPS |
-2.02 |
-2.98 |
-2.74 |
-1.87 |
-2.47 |
-2.33 |
-2.98 |
-3.02 |
-2.04 |
-0.89 |
| EPS Diluted |
-2.02 |
-2.98 |
-2.74 |
-1.87 |
-2.47 |
-2.33 |
-2.98 |
-3.02 |
-2.04 |
-0.89 |
| Weighted Average Shares
Out |
$75.97 M
|
$68.66 M
|
$67.62 M
|
$58.61 M
|
$49.98 M
|
$47.10 M
|
$40.32 M
|
$32.22 M
|
$35.70 M
|
$15.44 M
|
| Weighted Average Shares
Out Diluted |
$75.97 M
|
$68.66 M
|
$67.62 M
|
$58.61 M
|
$49.98 M
|
$47.10 M
|
$40.32 M
|
$32.22 M
|
$35.70 M
|
$15.44 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
